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Pharmacological propertiesAbstract Over the past decades, various studies have highlighted the pure natural compound,
a-mangostin as their main topic. The compound’s pre-clinical and pharmacological properties have
been recognized and deﬁned in these studies. a-Mangostin shows strong pharmacological effects in
in vitro and in vivo model systems by targeting a number of vital cellular factors through various
mechanisms of action. Despite its important molecular versatility, the a-mangostin still has limited
clinical application. In order to optimize the conditions of this compound as a chemotherapeutic
and chemopreventive agent, for instance in diseases such as cancer, obesity, diabetes as well asygenase;
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Figure 1 Chemical structu
318 M.Y. Ibrahim et al.inﬂammatory disorders, the recent tendency is to limit the range of its pharmacological properties.
The present work reviews recent studies on the central and potential pharmacological principles as
well as the preclinical applications of the a-mangostin.
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In recent times, the focus on plant research around the world
has increased; numerous lines of evidence have been gathered
to demonstrate the enormous potential of medicinal plants.
By means of modern scientiﬁc approaches, different types of
medicinal plants have been recognized and studied. The results
reveal these medicinal plants as having a promising potential,
particularly in pharmacology (Fiala et al., 1985; Tapsell et al.,
2006; Triggiani et al., 2006).
A number of human diseases have been associated with oxi-
dative stress; these include diabetes, cardiovascular diseases,
neurodegenerative disorders and especially carcinogenesis
(Nakabeppu et al., 2006; Triggiani et al., 2006). As a result,
a lot of interest is given toward researching naturally occurring
protective antioxidants as well as their mechanisms of action.
In accordance with this, it has been revealed that a number
of plant extracts or their secondary metabolites demonstrate
powerful antioxidant activity and the ability to protect from
oxidant-induced damages (Collins, 2005; Hayatsu et al.,
1988; Loo, 2003; Triggiani et al., 2006). Consequently, it was
observed in the last decade that a lot of plant extracts have
exhibited potent cancer chemopreventive properties
(Ames, 1998; Ames and Gold, 1998; Beckman and Ames,re of a-mangostin.1998; Borek, 2004; Cassady et al., 1990). For most of these
extracts, their effects are known to be achieved via antioxidant
mechanisms that either quench reactive oxygen species,
stimulate cellular antioxidant defense systems or prevent lipid
peroxidation (Carilli and Yun, 2000; Valko et al., 2007).
Mangosteen (Garcinia mangostana) Linn is a type of fruit that
grows in the Asian region such as Malaysia, Myanmar, Thai-
land, Philippines, Sri Lanka and India. Mangosteen is also
referred to as the ‘‘queen of fruits’’ due to its unique and delec-
table tropical taste. The fruit is dark purple or reddish in color
and contains soft and juicy edible white pulps inside. The ﬂa-
vor is slightly acidic and sweet and it has a delightful smell
(Jung et al., 2006). The pericarps of this fruit have been used
for many years as traditional medicine in treating sicknesses
such as trauma, skin infection, abdominal pain, dysentery
and wounds (Peres et al., 2000). Moreover, mangosteen has
been proven to contain various secondary metabolites (e.g.
prenylated and oxygenated xanthones) (Govindachari et al.,
1971; Peres et al., 2000). In 1855, a-mangostin (Fig. 1) was
found among the major xanthones taken from the pericarps
of the mangosteen fruit (Schmid, 1855). The compound is a
yellowish coloring matter which can be obtained from the
other parts of the plant as well, such as the dried sap and
the bark (Dragendorff, 1930). Subsequently, the structure of
this xanthone was construed by Dragendorff (1930) and
Murakami (1932). The molecular formula, type and position
of the substituent groups of a-mangostin were then determined
by Yates and Stout (1958). This compound has been discov-
ered to possess a wide range of biological activities, with
anti-inﬂammatory, anti-tumor, cardioprotective, antidiabetic,
antibacterial, antifungal, antiparasitic, antioxidant and anti-
obesity agents. In this paper, we review the main pharmacolog-
ical effects of this pure compound.
Table 1 Antioxidant properties of a-mangostin.
Eﬀect Reference
a-Mangostin showed antioxidant properties using the ferric thiocyanate
method
Fan and Su (1997) and Yoshikawa et al. (1994)
a-Mangostin is acting as a free radical scavenger to protect the LDL from
oxidative damage
Williams et al. (1995)
Structural modiﬁcation of a-mangostin can inhibit the oxidation of LDL Mahabusarakam et al. (2000)
a-Mangostin showed antioxidant activities using authentic and
morphosydnonimine-derived roxynitrite methods
Jung et al. (2006)
a-Mangostin has a protective eﬀect on lipid peroxidation and antioxidant
tissue defense system during ISO-induced myocardial infarction in rats
Devi Sampath and Vijayaraghavan (2007)
a-Mangostins inhibited nitric oxide (NO) from lipopolysaccharide (LPS)-
stimulated RAW 264.7 cells
Chen et al. (2008)
a-Mangostin can be an eﬀective cardiotoxic preventative against b-
adrenergic catecholamine induced myocardial toxicity and associated
oxidative stress
Devi Sampath and Vijayaraghavan (2007)
a-Mangostin attenuated renal dysfunction, structural damage, oxidative/
nitrosative stress and decreased the catalase expression in rats
Pe´rez-Rojas et al. (2009)
a-Mangostin has the ability to scavenge several ROS and has a
neuroprotective eﬀect against 3-NP in primary cultures of CGNs, which is
associated with its ability to ameliorate 3-NP-induced ROS production
Pe´rez-Rojas et al. (2009)
a-Mangostin protects renal tubular cells by blocking CDDP-induced
apoptosis through ROS generation and p53 signaling
Sa´nchez-Pe´rez et al. (2010)
a-Mangostin induces a protective eﬀect in postischemic heart associated
with the prevention of oxidative stress secondary to reperfusion injury
Buelna-Chontal et al. (2011)
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Mangosteen pericarps collected were dried, ground and
extracted separately in water and 50% ethanol. The 50% eth-
anol extract was freeze-dried and subsequently, the dried pow-
der resulting from the freeze-drying process was suspended in
water that was partitioned with ethyl acetate. Then, the ethyl
acetate extract was puriﬁed by chromatography on silica gel
with the n-hexane–ethyl acetate system and recrystallized to
achieve >98% purity of the compound (Mahabusarakam
et al., 1987; Parveen et al., 1991).
3. Main pharmacological properties of a-mangostin
3.1. Antioxidant properties
The antioxidant properties of a-mangostin which have been
studied are summarized in Table 1. These antioxidant proper-
ties were demonstrated through the ferric thiocyanate method
(Fan and Su, 1997; Yoshikawa et al., 1994). (Williams et al.,
1995) discovered that a-mangostin reduces copper- or peroxyl
radicals-induced oxidation of the human low density lipopro-
teins (LDL). They also found that a-mangostin: (i) dose-depen-
dently prolonged the lag time of conjugated dienes at 234 nm;
(ii) decreases the production of thiobarbituric reactive sub-
stances (TBARS); and (iii) diminishes the consumption of a-
tocopherol that is induced by LDL oxidation. In fact, this con-
sumption is also decreased by the synthetic derivatives of a-
mangostin. These authors also discovered that the antioxidant
activity of the a-mangostin could be modiﬁed by its structural
modiﬁcations. For instance, substituting C-3 and C-6 with ami-
noethyl derivatives caused the antioxidant activity to be
enhanced, whereas substituting them with methyl, propanediol,
acetate or nitrile resulted in a decrease of antioxidant activity
(Mahabusarakam et al., 2000). Furthermore, the IC50 (lM)value for ONOO scavenging on a 7,12-dimethyl-
benz[a]anthracene-induced mouse mammary organ culture
assay for different xanthones was determined by Jung et al.
(2006). a-Mangostin is one of the compounds that possesses
the highest capacity to scavenge ONOO- with 12.2 lM as
opposed to 3.1 lM for the positive control of DL-penicillamine.
The impact of a-mangostin on the antioxidant defense sys-
tem as well as on lipid peroxidation during myocardial infarc-
tion in rats induced by isoproterenol was evaluated by Devi
Sampath and Vijayaraghavan (2007). Results of this evaluation
revealed that there was a signiﬁcant decrease in the antioxidant
enzymes glutathione-S-transferase (GST), glutathione peroxi-
dase (GPx), catalase (CAT), superoxide dismutase (SOD) and
reduced glutathione (GSH) following the treatment with iso-
proterenol (150 mg/kg for 2 days). On the contrary, there was
a remarkable increase in serum enzymes, including creatine
phosphokinase (CPK), lactate dehydrogenase (LDH), gluta-
mate pyruvate transaminase (GPT), glutamate oxaloacetate
transaminase (GOT) and lipid peroxides. After being histopa-
thologically examined, rats treated with isoproterenol exhibited
necrotic alterations in the tissue, along with intense neutrophil
inﬁltration. These alterations were reduced signiﬁcantly by a 6-
day prior pretreatment with a-mangostin (200 mg/kg) and
2 days concurrently with isoproterenol administration. The
protective effect of this xanthone against lipid peroxidation
and toward the antioxidant defense system throughout
injury-induced myocardial infarction in rats was shown. In
addition, nitric oxide (NO) was also signiﬁcantly inhibited from
lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, and the
inhibition showed an IC50 value of 12.4 lM (Chen et al., 2008).
The wholesome effect of exogenously administered
a-mangostin against b-adrenergic catecholamine-induced
cardiovascular toxicity, especially with regard to membrane
ATPases, lysosomal hydrolases and inﬂammatory mediators
TNF-a and cyclooxygenase-2 (COX-2) expressions in albino
rats was explored by Devi Sampath and Vijayaraghavan
320 M.Y. Ibrahim et al.(2007). The result of a 2-day induction of rats with isoprotere-
nol (150 mg/kg body wt, i.p.) showed increasing serum and
cardiac lysosomal hydrolase (b-d-glucuronidase, b-d-galactosi-
dase, b-d-N-acetylglucosaminidase, acid phosphatase and
cathepsin-D) activities. Moreover, in the hearts of ISO-admin-
istered rats, the cardiac levels of sodium and calcium showed a
signiﬁcant increase, along with a decrease in the level of potas-
sium and abnormal activities of membrane-bound phospha-
tases (Na+–K+ ATPase, Ca2+ ATPase and Mg2+ ATPase).
Expressions of Cardiac TNF-a and COX-2 that were evalu-
ated using Western blotting showed a signiﬁcant elevation in
ISO-intoxicated rats. An 8-day oral pre-co-treatment with a-
mangostin (200 mg/kg body wt) mitigated these abnormalities
signiﬁcantly and restored the levels to near normalcy as
opposed to the ISO-intoxicated group of rats. The preserva-
tion of myocardial membrane integrity as well as the extenua-
tion of inconsistent TNF-a and COX-2 expressions by
a-mangostin are made possible by effectively mitigating
ISO-induced oxidative stress and cellular damage. The
cytoprotective role of a-mangostin is proven by the restoration
of cellular normalcy.
The renoprotective effect of a-mangostin on cisplatin
(CDDP)-induced nephrotoxicity in rats was evaluated by
Pe´rez-Rojas et al. (2009). 12.5 mg/kg/day, i.g. of a-mangostin
was administered for 10 days (7 days prior to and 3 days fol-
lowing CDDP injection). On the 7th day, the rats were treated
with a single injection of CDDP (7.5 mg/kg, i.p.). After 3 days,
the rats were killed. Effects of a-mangostin include the attenu-
ation of renal dysfunction, oxidative/nitrosative stress and
structural damage. The compound also abated the decrease
in catalase expression and increases in mRNA levels of tumor
necrosis factor alpha as well as transformed growth factor
beta. In a nutshell, the attenuation in oxidative/nitrosative
stress, inﬂammatory and ﬁbrotic markers as well as preserva-
tion of catalase activity are inherent in the renoprotective
effect of a-mangostin on CDDP-induced nephrotoxicity.
Pe´rez-Rojas et al. (2009) discovered the ability of a-mango-
stin to scavenge singlet oxygen, superoxide anion and perox-
ynitrite anion in a concentration-dependent manner. On the
contrary, the compound was unable to scavenge hydroxyl rad-
icals and hydrogen peroxide. a-Mangostin was also able to
improve the neuronal death induced by 3-nitropropionic acid
(3-NP) in a concentration-dependent manner. This protective
effect of the a-mangostin was related to the amelioration of
3-NP-induced reactive oxygen species formation.
In a study conducted by Sa´nchez-Pe´rez et al. (2010) to eval-
uate the ability of a-mangostin in protecting proximal tubule
renal epithelial cells (LLC-PK1) from cisplatin CDDP-induced
apoptotic death, cells were co-incubated with 5 lM a-M and
100 lM CDDP for a 24-h period. Results revealed that the fol-
lowing alterations were attenuated by a-mangostin: apoptotic
cell death, glutathione depletion, as well as increase in reactive
oxygen species and p53 expression induced by CDDP. The
preventive effect of a-mangostin on CDDP-induced apoptotic
death is attributable to the inhibition of p53 expression and
ROS generation.
The protective effect of a-mangostin on cardiac reperfusion
damage was investigated by Buelna-Chontal et al. (2011). The
ﬁndings indicate that a-mangostin preserves the mechanical
work of the cardiac, reduces the area of infarct as well as pro-
hibits the decrease in cardiac ATP and phosphocreatine levels
in the reperfused myocardium. This particular protective effectof the xanthone was afﬁliated with the reduction of oxidative
stress. Moreover, treatment with a-mangostin was found to
prevent the following: reperfusion injury-induced protein oxi-
dation (i.e. protein carbonyl content), diminution of glutathi-
one content and lipid peroxidation (i.e. malondialdehyde and
4-hydroxynonenal content).3.2. Anticancer and cytotoxic properties
As shown in Table 2, the anticancer and cytotoxic properties
of a-mangostin that is isolated from the pericarp of the
mangosteen fruit have been explored through a number of
studies.
In a study conducted by Matsumoto et al. (2003), the inhib-
itory effects of a-mangostin and 5 other xanthones on the cell
growth of the human leukemia cell line HL60 were explored.
The cytotoxic effects were examined 72 h following cell incuba-
tion with a-mangostin at 5 or 40 lM. a-Mangostin was found
to be especially effective from 10 lM and displayed the highest
inhibitory activity (IC50 10 lM) compared to other xanthones,
although they also exhibited signiﬁcant suppression effect.
Afterwards, other leukemia cell lines (K562, NB4 and U937)
showed the a-mangostin effect as well. a-Mangostin inhibited
the cell growth of the abovementioned leukemic cell lines at
5–10 lM.
The ability of a-mangostin administered in the diet to exert
short-term chemopreventive effects on 1,2-dimethylhydrazine
(DMH)-induced putative preneoplastic lesions in rat colon
carcinogenesis through subcutaneous injection (40 mg/kg body
wt, administered once a week for 2 weeks) was examined by
Nabandith et al. (2004). The ﬁndings showed that administer-
ing a-mangostin in the diet could signiﬁcantly inhibit the
release of biomarkers for DMH-induced short term colon
carcinogenesis (such as dysplastic foci, aberrant crypt foci
and b-catenin accumulated crypt).
Sato et al. (2004) conducted a study to examine the cell
death effects of eight xanthones on PC12 rat pheochromocy-
toma cells. It was discovered that a-mangostin obtained from
the fruit hull of G. mangostana L. had the most potent effect
among the eight compounds, with the EC50 value of 4 lM.
PC12 cells treated with a-mangostin displayed typical apopto-
tic DNA fragmentation and caspase-3 cleavage (equivalent to
activation). The time- and concentration-dependent manners
of the apoptosis induced by a-mangostin were indicated by
the ﬂow cytometric analysis. a-Mangostin also exhibited fea-
tures of the mitochondrial apoptotic pathway, including mito-
chondrial membrane depolarization and cytochrome c release.
Moreover, a-mangostin remarkably inhibited the sarco/
endoplasmic reticulum Ca2+-ATPase. The Ca2+-ATPase
inhibitory effects and the apoptotic effects of the xanthone
derivatives showed a correlation with each other. On the
contrary, a-mangostin treatment caused one of the signaling
molecules of endoplasmic reticulum (ER) stress, c-Jun NH2-
terminal kinase (JNK/SAPK), to be activated. These ﬁndings
imply that a-mangostin inhibits Ca2+-ATPase to bring about
apoptosis through the mitochondorial pathway.
The antiproliferative effect of a-mangostin along with 3
other prenylated xanthones in DLD-1 human colon cancer
cells was studied by Matsumoto et al. (2005). It was found that
a-mangostin strongly suppressed cell growth at 20 l and its
antiproliferative efﬁcacy was associated with the number of
Table 2 Anticancer and cytotoxic properties of a-mangostin.
Eﬀect Reference
a-Mangostin showed complete inhibition at 10 lM through the induction of
apoptosis on human leukemia cell line HL60
Matsumoto et al. (2003)
Crude a-mangostin has a potent chemopreventive eﬀect in short-term colon
carcinogenesis in rats
Nabandith et al. (2004)
a-Mangostin Induces Ca2+-ATPase-dependent apoptosis via mitochondrial
pathway in PC12 cells
Sato et al. (2004)
a-Mangostin induces cell-cycle arrest and apoptosis in human colon cancer DLD-1
cells
Matsumoto et al. (2005)
a-Mangostin has cytotoxic eﬀect against breast cancer (BC-1) and epidermoid
carcinoma of the mouth (KB) cells
Suksamrarn et al. (2006)
a-Mangostin-induced cell death: caspase-independent apoptosis with release of
endonuclease-G from mitochondria and increased miR-143 expression in human
colorectal cancer DLD-1 cells
Nakagawa et al. (2007)
a-Mangostin suppresses Pc-3 human prostate carcinoma cell metastasis by
Inhibiting Matrix Metalloproteinase-2/9 and urokinase-plasminogen expression
through the JNK signaling pathway
Hung et al. (2009)
a-Mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9
expressions via avb3 Integrin/FAK/ERK and NF-jB signaling pathway in human
lung adenocarcinoma A549 cells
Shih et al. (2010)
a-Mangostin suppresses TPA-Mediated MMP-2 and MMP-9 expressions through
the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells
Lee et al. (2010)
a-Mangostin has cytotoxic properties against head and neck squamous cell
carcinoma (HNSCC) cell lines
Kaomongkolgit et al. (2011)
a-Mangostin has potential cytotoxic eﬀect against human melanoma SK-MEL-28
cell line
Wang et al. (2011)
a-Mangostin Inhibits the proliferation of colon cancer cells via b catenin gene
regulation in Wnt/cGMP signaling pathway
(Yoo et al., 2011)
a-Mangostin reduces tumor growth and lymph node metastasis in an
immunocompetent xenograft model of metastatic mammary cancer carrying a p53
mutation
Shibata et al. (2011)
a-Mangostin induced apoptotic cell death against canine osteosarcoma D-17 cells Krajarng et al. (2012)
a-Mangostin showed potent eﬀects against HCT 116 colorectal carcinoma in an
in vitro and in vivo
Aisha et al. (2012)
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was attributable to cell-cycle arrest by affecting the cyclins,
cdc2 and p27 expression.
A study conducted by Suksamrarn et al. (2006) revealed
that a-mangostin exerted potent effect on breast cancer (BC-
1) cells at a lower IC50 value (0.92 lg/mL) compared to that
of the standard drug ellipticine (IC50 = 1.46 lg/mL). The
compound also exerted cytotoxic effects against epidermoid
carcinoma of the mouth (KB) cells (IC50 = 2.08 lg/mL).
Nakagawa et al., 2007 evaluated a-mangostin for in vitro
cytotoxicity against DLD-1 human colon cancer cells. They
found that treatment with 20 lM of a-mangostin reduced the
number of viable cells consistently. As implied by morpholog-
ical ﬁndings, the cytotoxic effect of 20 lM a-mangostin was
discovered to be largely due to apoptosis. Although no signs
of activation of any of the caspases tested were shown through
Western blotting, the results of an apoptosis inhibition assay
using caspase inhibitors and the examination of caspase activ-
ity, the release of endonuclease-G from mitochondria with the
decreased mitochondrial membrane potential were shown. In
the early phase, there was an increase in the levels of phos-
pho-Erk1/2 until 1 h following the beginning of treatment;
the levels subsequently decreased and then increased again in
the late phase. However, the level of phospho-Akt showed a
sharp decline with the process of apoptosis following 6 h
of treatment. One interesting ﬁnding is that the levelof microRNA-143, which negatively regulates Erk5 at
translation, increased gradually until 24 h after the treatment.
The synergistic growth suppression in DLD-1 cells was also
examined by treating the cells with a combination of a-mango-
stin and 5-FU, a chemotherapeutic agent that is deemed as one
of the most effective against colorectal adenocarcinoma. At
2.5 lM each, the co-treatment with a-mangostin and 5-FU
enhanced growth inhibition as opposed to solely treating the
cells with 5 lM of a-mangostin or 5 lM 5-FU individually.
These ﬁndings show the distinctive a-mangostin-induced apop-
tosis mechanisms and its action as an effective chemosensitizer.
The researchers found that treatment with 20 lM a-mangostin
reduced the number of viable cells.
The antimetastatic effects of a-mangostin against human
prostate carcinoma cell line PC-3 was found in a study by
Hung et al. (2009). In addition, treatment with a-mangostin
could decrease the expressions of the following enzymes in a
concentration-dependent manner: matrix metalloproteinase-2
(MMP-2), matrix metalloproteinase-9 (MMP-9) and uroki-
nase-plasminogen activator (u-PA). a-Mangostin also demon-
strated an inhibitory effect against the phosphorylation of
c-Jun N-terminal kinase 1 and 2 (JNK1/2) as well as inhibited
the activation of nuclear factor kappa B (NF-jB), c-Fos, and
c-Jun. Furthermore, the treatment with JNK-speciﬁc inhibitor
(SP600125) could reduce MMP-2, MMP-9 and u-PA
expression in PC-3 cells. These results demonstrated the ability
322 M.Y. Ibrahim et al.of a-mangostin to mediate PC-3 cells metastasis through the
reduction of MMP-2, MMP-9 and u-PA expression, which is
done by suppressing the JNK1/2 signaling pathway and inhib-
iting NF-jB and AP-1 binding activity.
Lee et al. (2010) discovered the effectiveness of a-mangostin
as an antimetastatic agent against the expressions of 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced matrix
metalloproteinase-2 (MMP-2) and matrix metalloproteinase-
9 (MMP-9) in human breast adenocarcinoma cells, MCF-7.
Moreover, a-mangostin inhibited the activation of extracellu-
lar signal-regulated kinase 1 and 2 (ERK1/2) that takes place
in the down-regulation of TPA-induced enzyme activities, pro-
tein, and MMP-2 and MMP-9 messenger RNA levels, as well
as TPA-induced degradation of inhibitor of kappaBa (IjBa)
and the nuclear levels of nuclear factor kappa B (NF-jB),
c-Fos, and c-Jun. In addition, a-mangostin treatment also
resulted in a dose-dependent inhibition of the binding abilities
of NF-jB and activator protein-1 (AP-1). Furthermore, MCF-
7 cells treated with the speciﬁc inhibitor for ERK (U0126)
could inhibit TPA-induced MMP-2 and MMP-9 expressions
as well as cell invasion and migration. Results revealed the
effectiveness of a-mangostin as a novel and effective antimeta-
static agent that acts through the down-regulation of MMP-2
and MMP-9 gene expressions.
Shih et al. (2010) investigated the anti-metastatic effect pos-
sessed by a-mangostin that is exerted on phorbol 12-myristate
13-acetate (PMA)-induced matrix metalloproteinase-2 (MMP-
2) and matrix metalloproteinase-9 (MMP-9) expressions in
A549 human lung adenocarcinoma cells. a-Mangostin was
found to inhibit PMA-induced adhesion, invasion and migra-
tion. Moreover, a-mangostin could inhibit avb3 integrin, focal
adhesion kinase (FAK) and extracellular signal-regulated
kinase1/2 (ERK1/2) activation involved in the down-regula-
tion of the PMA-induced enzyme activities, protein and mes-
senger RNA levels of MMP-2 and MMP-9. a-Mangostin
also strongly inhibited the degradation of inhibitor of kap-
paBa (IjBa) and the nuclear levels of nuclear factor kappa
B (NF-jB) induced by PMA. It was also observed that a-
mangostin treatment resulted in a dose-dependent inhibition
on the binding abilities of NF-jB. The effect of a-mangostin
is further potentiated in the reduction of FAK or ERK1/2
phosphorylation by FAK small interfering RNA (FAK
siRNA). Finally, in a concomitant manner, MMP-2 and
MMP-9 expressions were signiﬁcantly down-regulated through
the transient transfection of ERK siRNA, with considerable
inhibition of cell invasion and migration.
Kaomongkolgit et al. (2011) examined the apoptotic effect
exerted by a-mangostin in the human head and neck squamous
carcinoma cells (HNSCC) HN-22, HN-30 and HN-31. The
results showed that a-mangostin had exceptional apoptotic
effects on HNSCC cell lines, which induced the down-regula-
tion of bcl-2, while on the other hand caused an up-regulation
of bax and p53 in HN-22, HN-30 and HN-31.
In a study by Wang et al. (2011), the cytotoxic effect of
xanthone compounds (a-mangostin, c-mangostin, and
8-deoxygartanin) obtained from the pericarp of mangosteen
was examined using the human melanoma SK-MEL-28 cell
line. All of the tested compounds were found to induce apop-
tosis; especially a-mangostin which induced 59.6% early apop-
tosis at 7.5 lg/mL, compared to merely 1.7% in untreated
cells. This apoptotic effect was due to caspase activation and
mitochondrial membrane pathway disruption as shown by a25-fold increase in caspase-3 activity and 9-fold decrease in
mitochondrial membrane potential when compared to
untreated cells.
Yoo et al. (2011) found that a-mangostin has a potential
inhibitory effect against the Wnt/b-catenin signaling pathway.
a-mangostin inhibited TCF/b-catenin transcriptional activity
and b-catenin protein expression in colon cancer cells. How-
ever, instead of being dependent on b-catenin phosphorylation
and degradation, the inhibition b-catenin resulted from it gene
regulation, as indicated by increased cGMP and cGMP-
dependent kinase levels.
(Shibata et al., 2011) discovered the effect of a-mangostin in
reducing tumor growth and lymp node metastasis. The study
was conducted using an immunocompetent xenograft model
of mouse metastatic mammary cancer which carried a p53
mutation that induces a metastatic spectrum similar to the
one observed in human breast cancers. Prior to treatment,
mammary tumors were induced by inoculating BALB/c mice
syngeneic with metastatic BJMC3879luc2 cells. Treatment
with a-mangostin was performed at 0, 10 and 20 mg/kg/day
by means of mini-osmotic pumps and tumors were then hist-
opathologically examined. Furthermore, in vitro studies were
conducted to investigate the antitumor mechanisms of a-
mangostin. The results showed that besides having a signiﬁ-
cantly higher in vivo survival rates compared to controls, the
20 mg/kg/day a-mangostin group also showed suppression of
tumor volume and the multiplicity of lymph node metastases.
Mammary tumors of mice that were given 20 mg/kg/day dem-
onstrated a signiﬁcant increase in apoptotic levels due to
increased active caspase-3 and -9 expression. It was observed
that this particular dose level also produced other considerable
effects such as decreased micro vessel density and lesser num-
bers of dilated lymphatic vessels with intraluminal tumor cells
in mammary carcinoma tissues. Mitochondria-mediated apop-
tosis, G1-phase arrest and S-phase suppression in the cell cycle
were induced by a-mangostin in vitro. Considering the vital
role of the activation by Akt phosphorylation in various onco-
genic processes such as cell proliferation, anti-apoptotic cell
death, angiogenesis and metastasis, in vitro and in vivo investi-
gations of the alterations in Akt phosphorylation induced by
a-mangostin treatment were also conducted. Based on quanti-
tative analysis and immunochemistry, a-mangostin was shown
to signiﬁcantly decrease phospho-Akt-threonine 308 (Thr308)
levels in mammary carcinoma cell cultures and mammary car-
cinoma tissues in vitro, whereas this is not the case for serine
473 (Ser473).
(Krajarng et al., 2012) examined the antiproliferative effect
of a-mangostin in D-17 canine osteosarcoma cells. According
to the results, antiproliferation induced by a-mangostin
showed an IC50 value of 15 lg/ml. Nuclear condensation and
fragmentation, normally observed in apoptosis, were also
induced by a-mangostin, as revealed through Hoechst 33,342
nuclear staining and nucleosomal DNA-gel electrophoresis.
a-Mangostin was also able to induce sub-G1 peak as demon-
strated by cell-cycle analysis, as well as membrane ﬂipping of
the phosphatidylserine and the loss of mitochondrial mem-
brane potential in D-17 cells.
The anti-colon cancer effects (including cytotoxicity, apop-
tosis, anti-tumorigenicity as well as effects on cell signaling
pathways) of 81% a-mangostin and 16% c-mangostin xant-
hones extract on HCT 116 human colorectal carcinoma cells
were examined by (Aisha et al., 2012). Investigation of the
Table 3 Anti-inﬂammatory, antiallergy and analgesic properties of a-mangostin.
Eﬀect Reference
CNS depression (ptosis, sedation, decreased motor activity, potentiation of
pentobarbital sleeping time, ether anesthesia) in mice and rats
Shankaranarayan et al. (1979)
Signiﬁcant antiulcer eﬀect in rats Shankaranarayan et al. (1979)
Prohibition of systemic anaphylaxis, immunocytoadherence in guinea pigs and rats,
and inhibition of the primary and secondary responses of adjuvant-induced arthritis
in rats
Gopalakrishnan et al. (1980)
Histaminergic and a serotonergic receptor blocking agent Chairungsrilerd et al. (1996))
a-Mangostin suppressed histamine-induced contractions in rabbit thoracic aorta
and guinea-pig trachea in a dose of dependent manner.
Chairungsrilerd et al. (1996)
Inhibition of 12-human lipoxygenase (12-LOX) Deschamps et al. (2007)
a-Mangostin suppressed the degranulation in Ag-mediated activation of IgE
receptors in rat basophilic leukemia RBL-2H3 cells through SYK/PLCcs/PKC
pathway
Itoh et al. (2008)
Anti-inﬂammatory activity by inhibition of inducible NO synthase and cytotoxicity
to mouse leukemic monocyte macrophage cell line (RAW 264.7 cells)
Chen et al. (2008)
Analgesic and antinociceptive activity Cui et al. (2010)
a-Mangostin inhibits allergic mediators in bone marrow-derived mast cell Chae et al. (2012)
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subcutaneous tumors formed in nude mice. The xanthones
extract demonstrated strong cytotoxicity through induction
of the mitochondrial apoptosis pathway, with a median inhib-
itory concentration of 6.5 ± 1.0 lg/ml. In addition, the extract
was found to inhibit cell migration, invasion and clonogenici-
ty, which are three main steps in tumor metastasis. MAPK/
ERK, c-Myc/Max, and p53 cell signaling pathways were also
up-regulated. The xanthones extract also inhibited the growth
of subcutaneous tumor of HCT 116 colorectal carcinoma cells
signiﬁcantly when fed to the nude mice. In summary, all of the
above results indicate that a-mangostin would be a suitable
candidate for preventive and therapeutic applications in cancer
treatment.
3.3. 3Anti-inﬂammatory, anti-allergy analgesic properties
In Table 3, the anti-inﬂammatory and anti-allergy properties
of a-mangostin that have been studied are summarized.
(Shankaranarayan et al., 1979)studied the diverse pharmaco-
logical effects of a-mangostin and its derivatives [namely 3-0-
methyl mangostin, 3,6-di-O-methyl mangostin, 1-isomangostin
(IM), mangostin triacetate (MT), mangostin 3,6-di-O-(tetra
acetyl) glucoside (MTG) and mangostin-6,6-di-O-glucoside
(MOG)] in experimental animals. a-mangostin was found to
produce CNS depression in mice and rats; characteristics of this
depression include sedation, ptosis, decreased motor activity,
potentiation of pentobarbital sleeping time and ether anesthesia.
Moreover, based on the results of carrageenan-induced hind
paw edema, cotton pellet implantation and granuloma pouch
techniques, a-mangostin produced prominent anti-inﬂamma-
tory activity in rats, via both intraperitoneal and oral routes.
In fact, this anti-inﬂammatory activity was present in bilaterally
adrenalectomized rats as well. No mast cell membrane stabiliz-
ing effect was produced by the compound, and it did not prevent
the degranulation effects of polymyxin B, diazoxide and Triton
X-100 on rat peritonealmast cells in vitro. The prothrombin time
of albino rats was also not altered. Finally, administration of a-
mangostin in rats revealed considerable antiulcer activity of the
compound.The effect of a-mangostin in prohibiting systemic anaphy-
laxis and immunocytoadherence in guinea pigs and rats was
demonstrated in a study by (Gopalakrishnan et al., 1980).
The study also found that this compound, isolated from the
rinds of the mangosteen, could also inhibit primary and sec-
ondary responses of adjuvant-induced arthritis in rats.
(Chairungsrilerd et al., 1996) showed the ability of the
methanolic extract of mangosteen-fruit pericarp to inhibit
histamine- and serotonin-induced contractions of isolated
rabbit thoracic aorta. The authors suggested that a-mango-
stin is a histaminergic receptor blocking agent, whereas c-
mangostin is a serotonergic receptor blocking agent. The
same research group evaluated the effect of a-mangostin
on the contractions of rabbit thoracic aorta and guinea-pig
trachea induced by histamine. Results revealed that either
with or without cimetidine (the H2-histamine receptor antag-
onist), a-mangostin could dose-dependently suppress con-
tractions induced by histamine. Contractions that are
mediated by the histamine H1 receptor were also prohibited.
In addition, a speciﬁc histamine H1 receptor antagonist
binding to rat aortic smooth muscle cells, [3H] mepyramine,
was also suppressed competitively by a-mangostin.
(Deschamps et al., 2007) showed the ability of a-mango-
stin to inhibit 12-human lipoxygenase (12-LOX) at an IC50
value of 0.58 lM. The intracellular signal transductions acti-
vated by the IgE receptor caused the inﬂammatory signal
mediators such as histamine to be released, which is a pri-
mary event in a number of allergic responses. This informa-
tion became the basis for (Itoh et al., 2008) to demonstrate
that the degranulation in Ag-mediated activation of IgE
receptors was suppressed by a-mangostin in rat basophilic
leukemia RBL-2H3 cells. The authors suggested that sup-
pression of the SYK/PLCcs/PKC pathway played the main
role in the inhibitory mechanism of degranulation by a-
mangostin.
In addition, Chen et al. (2008) demonstrated the signiﬁ-
cant effect of a-mangostin in the inhibition of lipopolysac-
charide-stimulated NO production and cytotoxicity in
mouse leukemic monocyte macrophage cell line (RAW
264.7 cells). At 3–25 lM a-mangostin, the amount of
Table 4 Antibacterial, antifungal and antiviral properties of a-mangostin.
Eﬀect Reference
a-Mangostin and four of its derivatives have antibacterial eﬀect against S. aureus, P.
aeruginosa, Salmonella typhimurium and Bacillus subtilis, Klebsiella sp. and
Escherichia coli
Sundaram et al. (1983)
a-Mangostin and four of its derivatives has antibacterial eﬀect against
Epidermophyton ﬂoccosum, Alternaria solani, Mucor sp., Rhizupus sp. ,
Cunninghamella echinulata, Trichophyton mentagrophytes, Microsporum canis,
Aspergillus niger, Aspergillus ﬂavus, Penicillium sp., Fusarium roseum and Curvularia
lunata
Sundaram et al. (1983)
a-Mangostin showed high eﬃcacy against the growth of methicillin-resistant S.
aureus (MRSA)
Iinuma et al. (1996))
a-Mangostins inhibits HIV-1 protease Chen et al. (1996)
a-Mangostin-derivatives have antifungal properties against three phytopathogenic
fungi (Fusarium oxysporum vasinfectum, Alternaria tenuis and Dreschlera oryzae)
Gopalakrishnan et al. (1997)
Inhibiting role in the replication cycle of HIV virus Vlietinck et al. (1998)
Potent inhibitory eﬀect against Mycobacterium tuberculosis Suksamrarn et al. (2003)
a-Mangostin have inhibitory activity against vancomycin resistant Enterococci
(VRE) and Methicillin-resistant Staphylococcus aureus (MRSA)
Sakagami et al. (2005)
Antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) Chin and Kinghorn (2008))
a-Mangostin has eﬀective antifungal properties against Candida albicans Kaomongkolgit et al. (2009)
a-Mangostin metabolized by two fungi, Colletotrichum gloeosporioides (EYL131)
and Neosartorya spathulata (EYR042)
Arunrattiyakorn et al. (2011)
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value was 12.4. The production of PGE2 in lipopolysaccha-
ride-activated RAW 264.7 cells was also signiﬁcantly
reduced by a-mangostin, with IC50 value of 11.08 lM. To
probe the effect of this xanthone, the induction of inducible
nitric oxide synthase as well as COX enzyme expressions
was measured. a-Mangostin concentration was found to
reduce iNOS induction in a dependent manner. 1 lg/mL
lipopolysaccharide was used to activate the RAW 264.7 cells
for 12 h and iNOS activity in the activated RAW 264.7 mac-
rophages was observed to be weakly inhibited following a
24-h treatment with 5 lg/mL a-mangostin. Carrageenan-
induced paw edema in mice was used to evaluate the anti-
inﬂammatory effect of a-mangostin. Both a-mangostin and
sulindac (reference compound) potently inhibited paw
edema. However, a-mangostin acted more rapidly, showing
potent inhibition at 3 h of treatment compared to 5 h of
treatment with sulindac.
Cui et al. (2010) showed that 25 mg/kg intragastric (i.g.)
a-mangostin exhibited analgesic effects in the hot-plate. More-
over, the results demonstrate the potent peripheral and central
antinociceptive effects exerted by a-mangostin in mice.
Chae et al. (2012) investigated the effect of a-mangostin on
the bone marrow-derived mast cell (BMMC) mediated allergy
mechanism induced by phorbol 12-myristate 13-acetate (PMA)
plus A23187. a-Mangostin was shown to inhibit the produc-
tion of Interleukin (IL)-6, prostaglandin D2 (PGD2) and leu-
kotriene C4 (LTC4) as well as degranulation in BMMC
induced by PMA plus A23187. Another effect of a-mangostin
that was observed was the repression of cyclooxygenase
(COX)-2 expression. These results reﬂect the potential useful-
ness of a-mangostin in alleviating allergic inﬂammatory
responses mediated by the mast cell.
The above data indicate that the anti-inﬂammatory, antial-
lergic and analgesic properties possessed by a-mangostin iso-
lated from the mangosteen fruit make it a novel and
promising compound.3.4. Antimicrobial properties
Table 4 shows a number of studies which have demonstrated
the antibacterial, antifungal and antiviral properties of a-
mangostin.
A study by Sundaram et al., 1983 on the antibacterial and
antifungal properties of a-mangostin as well as four of its
derivatives found that the following bacteria were highly sus-
ceptible to xanthones: S. aureus, P. aeruginosa, Salmonella
typhimurium and Bacillus subtilis. Klebsiella sp., Proteus sp.,
Klebsiella sp. and Escherichia coli showed moderate suscepti-
bility. Fungi that were found to be highly susceptible to xant-
hones include Epidermophyton ﬂoccosum, Alternaria solani,
Mucor sp., Rhizupus sp. and Cunninghamella echinulata,
whereas those found to be moderately susceptible were Trich-
ophyton mentagrophytes, Microsporum canis, Aspergillus niger,
Aspergillus ﬂavus, Penicillium sp., Fusarium roseum and Curvu-
laria lunata. The minimum inhibitory concentration, which is
the lowest concentration of an antimicrobial required to
inhibit the visible growth of a microorganism following over-
night incubation, of a-mangostin was between 12.5 and
50 lg/mL and between 1 and 5 lg/mL for bacteria and fungi,
respectively. The following is the order of the antibacterial and
antifungal efﬁciency: a-mangostin > isomangostin > 3-O-
methyl mangostin > 3, 6-di-O-methyl mangostin. On the
other hand, mangostin triacetate did not demonstrate any
activity.
(Iinuma et al., 1996) evaluated a few xanthones isolated
from the pericarp of mangosteen fruit for their inhibitory
effect against methicillin-resistant S. aureus (MRSA) growth.
Findings showed the high efﬁcacy of a-mangostin, with MIC
values ranging between 1.57 and 12.5 lg/mL.
(Chen et al., 1996; Iinuma et al., 1996) demonstrated
the effective inhibition of HIV-1 protease by the ethanolic
extract. Using Pepstatin A as a positive control at an IC50
value of 76 ± 5.5 nM, a-mangostin displayed an IC50 value of
5.12 ± 0.41 lM.
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itory activities of a-mangostin-derivatives against three phyto-
pathogenic fungi, namely Fusarium oxysporum vasinfectum,
Alternaria tenuis and Drechslera oryzae, by using 1, 10, 100
and 1000 ppm in the culture medium. Modiﬁcation in the
bioactivities of the compounds was observed following substi-
tution in A and C rings.
Vlietinck et al., 1998 discovered the role of a-mangostin as a
non-competitive inhibitor of HIV-1 protease by inhibiting the
HIV virus replication cycle.
Suksamrarn et al., 2003 conducted a study on prenylated
xanthones obtained from the pericarp of the mangosteen fruit
to examine the anti-tuberculosis potential. Results showed that
at an MIC value of 6.25 lg/mL, a-mangostin demonstrated
potent inhibitory effect against Mycobacterium tuberculosis.
(Sakagami et al., 2005) discovered the inhibitory activity of
a-mangostin against vancomycin resistant Enterococci (VRE)
with an MIC value of 6.25 as well as against Methicillin-
resistant Staphylococcus aureus (MRSA) with an MIC value
of 12.5 lg/mL.
In addition, (Chin and Kinghorn, 2008) demonstrated the
high efﬁcacy of a-mangostin in terms of its antibacterial activ-
ity againstMethicillin-resistant Staphylococcus aureus (MRSA)
with MIC value of 1.95 lg/mL and MBC value of 3.91 lg/mL.
The activity of a-mangostin against the most important
microorganism implicated in oral candidasis, namely Candida
albican, in comparison with Clotrimazole and Nystatin was
examined by Kaomongkolgit et al., 2009. a-Mangostin showed
to be effective at a minimum inhibitory concentration of
1,000 lg/ml and minimum fungicidal concentration (MFC)
of 2,000 lg/ml, exhibiting higher efﬁciency compared to
Clotrimazole and Nystatin. In determining its cytotoxicity, it
was revealed that at 4,000 lg/ml, a-mangostin was not toxic
to human gingival ﬁbroblast for 480 min. Hence, a-mangostin
can be a promising agent in treating oral candidiasis due its
low toxicity and strong antifungal activity.
(Arunrattiyakorn et al., 2011) studied the microbial metab-
olism of a-mangostin isolated from G. mangostana L on fungus
and found that two fungi metabolized a-mangostin; they are
Colletotrichum gloeosporioides (EYL131) and Neosartorya
spathulata (EYR042). The following four metabolites were
produced as a result of incubating a-mangostin with
C. gloeosporioides (EYL131): mangostin 3-sulfate (2),
mangostanin 6-sulfate (3), 17, 18-dihydroxymangostanin
6-sulfate (4) and isomangostanin 3-sulfate (5). Spectroscopic
data analysis was used to elucidate structures of the isolated
compounds.
3.5. Anti parasitic and anthelmintic properties
As shown in Table 5, Taylor and Mangostin, 2006 found that
a-mangostin showed moderate in vitro antiplasmodial activity
against Plasmodium falciparum with an IC50 value of 17 lM.
Bullangpoti et al., 2007 evaluated the extracts of mango-
steen pericarp (Garcina mangostana L.) for their efﬁciency as
an alternative control of Brown Plant Hopper (BPH) Thailand
strain. Toxicity was determined by topical spraying at different
nymphal and adult BPH stages. Compared to the other sol-
vents (hexane, acetone and dichloromethane), ethanol extract
of the mangosteen pericarp exhibited the best control of
BPH with LC50 value of 4.5% w/v (r2 = 0.95) and 3rd instarBPH nymphs. The LC50 value of the active compound,
a-mangostin, was 5.44%w/v (r2 = 0.88). Compared to Imida-
cloprid (LC50 of 0.0042% w/v (r2 = 0.99)), this extract had
less toxicity. In determining toxicity to non-target organisms,
it was found that the extract demonstrated toxicity to the
following: guppies (LC50 = 2.53 ppm for females and
4.27 ppm for males; r2 = 0.97 and 0.97, respectively), bees
(LC50 = 4.38% w/v, r
2 = 0.95) and mice (no oral acute toxic-
ity and dermal inﬂammation, only eye irritation which
occurred in 1 day and returned to normal within 3 days).
in vitro detoxiﬁcation enzyme activities from BPH, namely
carboxylesterase, acetylcholinesterase and glutathione-s-trans-
ferase, were observed following a 24-h exposure. Stronger
activity was exhibited by carboxylesterase compared to other
enzymes. In each generation, there was an increase of toxicity
in terms of LC50 values for treatments with both the extract
and imidacloprid. Following sequential spraying, each genera-
tion showed LC values of 4.22–6.67. The ethanol extract was
kept at different temperatures (4 C, room temperature and
55 C) for 3 months and it was found that at 55, the quantity
of a-mangostin and the BPH control efﬁciency was lower. The
above results indicate that besides causing minimal environ-
mental problems, the mangosteen pericarp extract possesses
high efﬁciency and causes less resistance in BPH, making it a
potential alternative insecticide for BPH control.
A study by Larson et al. (2010) to investigate the larvicidal
activity of a-mangostin against third instar larvae of six mos-
quito species found that the values of median lethal concentra-
tion range from 0.84 to 2.90 ppm. Subsequent to putting a-
mangostin under semi ﬁeld conditions to examine its residual
larvicidal activity, a-mangostin was found to be photolytic
with a half-life of 53 min in water under full exposure to sun-
light. Based on the results, a-mangostin signiﬁcantly elevated
P450 and glutathione S-transferase activities in larvae, but
on the contrary, esterase activity was suppressed. Following
a study on its toxicity against young rats, a-mangostin did
not demonstrate any adverse effects even at a high dosage of
80 mg/kg.
The activities of a-mangostin and mangostin diacetate, the
synthetic derivative, were studied by Keiser et al. (2012). Lack
of activity was observed for both a-mangostin and mangostin
diacetate against the following nematodes: Heligmosomoides
polygyrus (third-stage larvae (L3), Ancylostoma ceylanicum
L3, and Trichuris muris adults. A low activity level was
observed against A. ceylanicum adults (IC50s of 91 lg/ml)
in vitro, while promising activities were demonstrated by
a-mangostin against trematodes: Schistosoma mansoni,
Echinostoma caproni, and Fasciola hepatica in vitro, with IC50
value of 2.9–15.6 lg/mL. Worm burden reductions, ranging
from 0% to 38% (against S. mansoni) and 11–54% (against
E. caproni) were achieved by single oral doses of the drugs
(400 mg/kg and 800 mg/kg) in vivo.
3.6. Anti-obesity properties
Table 5 displays the in vitro cytotoxicity of a-mangostin
against 3T3-L1 cells and its inhibitory effect on fatty acid syn-
thase (FAS, EC 2.3.1.85) as discovered by Quan et al. (2012)).
Based on the research, a-mangostin with an IC50 value of
20 lM had incomplicated cytotoxicity in apoptotic events such
as increase of cell membrane permeability, mitochondrial
Table 5 Anti-parasitic, anthelmintic and anti-obesity properties of a-mangostin.
Eﬀect Reference
Moderate activity in an in vitro anti-plasmodial against Plasmodium falciparum Taylor and Mangostin (2006)
a-Mangostin can be an alternative insecticide for the control of Brown Plant
Hopper (BPH)
Bullangpoti et al. (2007)
a-Mangostin has a larvicidal eﬀect on botanic mosquito sterol carrier protein-2
inhibitor
Larson et al. (2010)
a-Mangostin has promising activities against the trematodes Schistosoma mansoni,
Echinostoma caproni, and Fasciola hepatica in vitro(IC50 of 2.9–15.6 lg/mL)
Keiser et al. (2012)
a-Mangostin has in vitro cytotoxicity against 3T3-L1 cells as well as inhibiting fatty
acid synthase (FAS, EC 2.3.1.85)
Quan et al. (2012)
Table 6 Pharmacokinetic studies of a-mangostin.
Assay Reference
A HPLC/MS assay has been established for the determination of a-mangostin in rat
plasma after oral and intravenous (i.v) injection. Non-compartmental analysis was
performed
Li et al. (2010)
An LC–MS/MS assay has been established for the determination of a-mangostin in
rat plasma after intravenous (i.v) and oral administration. Both non-compartmental
and compartmental analyses were performed
Li et al. (2011)
326 M.Y. Ibrahim et al.membrane potential (Dwm) loss and nuclear chromatin con-
densation. A decline of FAS activity in cells also occurred
along with this cytotoxicity, which could be rescued by
50 lM or 100 lM exogenous palmitic acids. This suggested
that a-mangostin induced the apoptosis of 3T3-L1 preadipo-
cytes by inhibiting FAS. a-Mangostin also showed its ability
to suppress intracellular lipid accumulation in differentiating
adipocytes and stimulated lipolysis in mature adipocytes; this
was associated to its inhibition of FAS as well. It was also
found that the susceptibility of 3T3-L1 preadipocytes toward
the cytotoxic effect of a-mangostin is higher compared to that
of the mature adipocytes. Further studies demonstrated that
inhibition of FAS by a-mangostin was probably due to stron-
ger action on the ketoacyl synthase domain and weaker action
on the acetyl/malonyl transferase domain. These ﬁndings sug-
gested the usefulness of a-mangostin in treating or preventing
obesity.
3.7. Treatment of Alzheimer’s disease (AD)
Wang et al. (2012) discovered that a-mangostin attenuated the
neurotoxicity induced by Ab-(1-40) or Ab-(1-42) oligomers,
with EC50 values of 3.89 nM and 4.14 nM respectively,
through decreased cell viability and impaired neurite out-
growth in primary rat cerebral cortical neurons in a concentra-
tion-dependent manner. The potential of a-mangostin to bind
to Ab and stabilize a-helical conformation was demonstrated
through molecular docking and dynamics simulations.
It was found that a-mangostin could dissociate Ab-(1-40)
and Ab-(1-42) oligomers directly via blotting with oligomer-
speciﬁc antibodies. Furthermore, the ability of a-mangostin
to block the ﬁbril formation and disturb the pre-formed ﬁbrils
was observed through ThioﬂavinT ﬂuorescence assay and elec-
tron microscopy imaging. All in all, these results point out the
capability of a-mangostin to inhibit and dissociate the Ab
aggregation, which could play a role in its effect of attenuatingAb oligomers-induced neurotoxicity. This suggests the great
potential of a-mangostin to be a candidate for AD treatment.
3.8. Pharmacokinetics Studies
Table 6 shows that in order to determine a-mangostin in rat
plasma, HPLC-MS assay was established, with bergamottin
as internal standard. The recovery percentage of a-mangostin
from the plasma samples was 93.19%. A linear calibration
curve, over the range of 20–2000 ng/ml was observed. Total
run time was 8 min, and the intra- and inter-assay variability
was less than 9.32% and 9.87%, respectively. a-Mangostin
showed within +15% accuracies when determined at the con-
centrations of 70, 850 and 1800 ng/mL. Following oral and
intravenous (i.v) injection, pharmacokinetic studies in rats
were supported successfully using the rapid, simple and precise
validated method. Non-compartmental and compartmental
analyses were performed, where the two-compartment body
model ﬁts well with the (i.v) data. Non-compartmental analysis
suggested a short half-life of 4 min and a low oral bioavailabil-
ity of only 4.24% for a-mangostin (Li et al., 2010). Subsequent
to (i.v) administration, a-mangostin exhibited biphasic disposi-
tion in rat plasma, which is subdivided into two phases: fast
distribution and slow elimination. The half-life of the distribu-
tion phase was 3 min, and that of the terminal elimination
phase 3.5 h, indicating a high tissue binding. However, for oral
administration, the bioavailability was so low that it was not
possible to obtain a full concentration–time proﬁle (Li et al.,
2011).4. Conclusion
The quest of discovering various pharmacological properties
and applications of a-mangostin is an endeavor that continues
to develop and progress rapidly. This is evident through the
a-Mangostin from Garcinia mangostana Linn 327numerous studies reviewed above as well as others that are
continuously being reported. Nevertheless, the extensive clini-
cal use of a-mangostin to treat various human diseases is con-
fronted with the pharmacokinetic constraints of this particular
compound. Despite that, this predicament is addressed
through an exceptional amount of work that is being con-
ducted by means of unique delivery systems and chemical
modiﬁcations. Another manner in which this work can be
advantageous to the realm of a-mangostin study is through
generating patentable drug constructs that could inﬂuence
major development and production of a-mangostin as a drug
by the prominent and afﬂuent pharmaceutical companies
around the world. The studies that are reviewed above illus-
trate the promising qualities and extensive potential preclinical
application of a-mangostin which are largely due to its diverse
pharmacological effects on nearly all major organ systems in
the animal models. These effects, accompanied by an equally
enormous amount of molecular targets and mechanisms of
action demonstrated in a large host of cell types both in vitro
and in vivo, further substantiated the strong potential of the
a-mangostin. In addition, preliminary studies have suggested
the safety of this natural compound for human administration,
therefore making a-mangostin a reliable agent that can be used
in the prevention and treatment of a wide array of human
pathological conditions, especially inﬂammatory-based pro-
cesses or even cancer. In implying the powerful effect of a-
mangostin for treating patients, we can perhaps relate to a
quote by Dr. Carl C. Pfeiffer, the author of Pfeiffer’s Law
who stated that ‘‘For every drug that beneﬁts a patient, there
is a natural substance that can achieve the same effect.’’
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